Coya Therapeutics Inc (COYA) — Titan Protect Analysis

COYA

Coya Therapeutics Inc

Healthcare · ·

$4.42

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$108M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-2.77

Based on estimated future earnings — lower means cheaper

Rev Growth

-2.6%

Year-over-year revenue change

Profit Margin

-266.1%

How much profit the company keeps from each dollar of revenue

ROE

-51.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$15.75

+256% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 6 analysts covering this stock

About Coya Therapeutics Inc

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated

https://www.coyatherapeutics.com

Country: United States Employees: 8 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.099

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0130

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.261

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-16.4%

Historical annualised return based on price data

Max Drawdown

-62.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.55

Less volatile than the market — more defensive

52W High

$7.75

43% below the year high

52W Low

$3.71

19% above the year low

Avg Volume

155,015

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.15

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

-96.7%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-3,038.2%

Profit from core operations before interest and tax

Free Cash Flow

$-9,747,224

Negative — the business is spending more than it generates

Revenue (TTM)

$8M

Total revenue over the last 12 months

Net Income

$-21,126,340

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$18.00

Target Median

$15.75

Target Low

$14.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go